Form 4: Veracyte CFO Sells Shares Under 10b5-1 Plan After Stock Vesting
SEC Form 4 Filing
Veracyte's Chief Financial Officer, Rebecca Chambers, sold 7,000 shares of common stock at an average price of $43.2317, following the vesting of restricted stock units and associated tax withholdings.
Summary
- Rebecca Chambers, the Chief Financial Officer of Veracyte, Inc., engaged in transactions involving the company's common stock.
- On December 2, 2024, 3,464 shares were withheld to cover tax obligations related to the vesting of restricted stock units.
- On December 3, 2024, Ms. Chambers sold 7,000 shares at a weighted average price of $43.2317, with individual sale prices ranging from $42.71 to $43.64.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 13, 2024.
- Following these transactions, Ms. Chambers directly owns 114,037 shares of Veracyte common stock.
Sentiment
Score: 5
Explanation: The document reflects routine insider trading activity under a pre-arranged plan, which is neither positive nor negative in itself.
Risks
- Sales by company insiders, even under pre-arranged plans, can sometimes be perceived negatively by the market.
Industry Context
Insider trading activity is a common occurrence in publicly traded companies, and sales under Rule 10b5-1 plans are generally viewed as routine and pre-planned.
Comparison to Industry Standards
- Rule 10b5-1 plans are a standard practice for corporate insiders to sell shares without being accused of trading on non-public information.
- The volume of shares sold is relatively small compared to the total outstanding shares of Veracyte, which is typical for routine insider sales.
- Comparable companies in the biotech and diagnostics space also see similar insider trading activity.
Stakeholder Impact
- The sale of shares by the CFO may have a minor impact on shareholder sentiment, but is unlikely to have a significant impact on the company's operations or financial health.
Key Dates
| Date | Description |
|---|---|
| July 19, 2021 | Date of grant for some of the restricted stock units that vested. |
| March 3, 2022 | Date of grant for some of the restricted stock units that vested. |
| August 5, 2022 | Date of grant for some of the restricted stock units that vested. |
| March 6, 2023 | Date of grant for some of the restricted stock units that vested. |
| August 13, 2024 | Date the Rule 10b5-1 trading plan was adopted. |
| December 2, 2024 | Date of tax withholding for vested restricted stock units. |
| December 3, 2024 | Date of sale of 7,000 shares. |
| December 4, 2024 | Date of filing of the Form 4. |
Keywords
Veracyte, VCYT, insider trading, Form 4, Rebecca Chambers, Rule 10b5-1, stock sale, CFO, restricted stock units, tax withholding
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.